Physician profile
Stacey A Blyth
NPI 1679553135
$2,200.50
in general payments reported to CMS, 2019-2025
25 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $334 · 2021: $273 · 2022: $253 · 2023: $472 · 2024: $320 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $372.64 | 2022-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
| Amgen INC. | $284.40 | 2019-2024 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $175.15 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $151.14 | 2019-2023 | Lokelma |
| Merck Sharp & Dohme LLC | $107.76 | 2019-2023 | Gardasil 9, M-M-R II, Pneumovax 23 |
| Abbvie INC. | $93.10 | 2022-2024 | |
| Glaxosmithkline, LLC. | $55.61 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $55.39 | 2019-2020 | |
| Pfizer INC. | $43.25 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $40.79 | 2019-2020 | |
| Organon LLC | $38.95 | 2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $33.17 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $29.16 | 2024 | Rexulti |
| Astellas Pharma US INC | $26.30 | 2023 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.89 | 2023 | |
| Janssen Pharmaceuticals, INC | $23.42 | 2019-2021 | |
| Genentech USA, INC. | $19.51 | 2020 | |
| Dynavax Technologies Corporation | $16.19 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $15.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.73 | 2023 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $14.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Blyth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.